Company announcement, Helsinki, 20 April 2016 at 9:00 am

  • Strengthened patent estate around Nexstim's cutting-edge technology and software

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces that the European Patent Office (EPO) has now granted a key patent covering its method and system for displaying the electric field generated on the brain by transcranial magnetic stimulation (TMS).

Nexstim's Navigated Brain Stimulation (NBS) is the world's most advanced navigated TMS system and the only one able to model the electric field in the brain. E-field based navigation enables enhanced accuracy, repeatability and dose control, to transform TMS as a clinical tool for personalised therapy.

This approval is in addition to our patents granted in China, Japan and USA covering this validated E-field navigation. Nexstim's patent portfolio includes 80 granted patents and 76 pending patents in 26 patent families.

TMS uses an induction coil in which a time-varying magnetic field is generated to induce an electric E-field within the brain. The neurons at the locations of the brain exposed to a strong enough E-field will become activated, or stimulated. In NBS, the E-field induced in the brain by a TMS induction coil device is shown as an overlay on a graphical display of an anatomical representation of the subject's brain. By viewing the display, a user can visualise the E-field and, therefore, interactively position the TMS coil device, in real time, in relation to the brain to stimulate a target site.

Commenting on the announcement, Janne Huhtala, CEO of Nexstim, said: "This patent adds further validation of Nexstim's technology, software and our unique E-field navigation. Whilst already used in both our systems, NBS and NBT®, this strengthens our platform's position as we lead the way in non-invasive neuromodulation."

NEXSTIM PLC
Janne Huhtala, CEO

For further information please visit www.nexstim.com or contact:

Nexstim                                                          +358 (0)40 8615046
Janne Huhtala, Chief Executive Officer  janne.huhtala@nexstim.com

UB Securities Ltd (Certified Adviser)          +358 (0)9 2538 0246

Consilium Strategic Communications         +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton  nexstim@consilium-comms.com

About Nexstim Plc
Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.

HUG#2004929